GM&C Life Sciences Fund
VC Fund
Alderley Edge, United Kingdom
GM&C Life Sciences Fund is a VC fund in Alderley Edge focused on Health Care and Biotechnology. The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers ("Catapult Ventures").The Fund is based at Alderley Park, which is well recognised as a site ofnational importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca.Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics). The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.
- Total investments:
- 36
- Last investment:
- Lead investor:
- 64%
Last updated:
For AI agents: llms.txt
Industries GM&C Life Sciences Fund invests in
Stages GM&C Life Sciences Fund invests in
Countries GM&C Life Sciences Fund invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 7 contacts → | |||
Round size
- Seed
- $94k–$1.9M
- Series A
- $1.9M–$4.2M
- Venture - Series Unknown
- $4.3M–$5.8M
Investment Focus
Industry
- Health Care 19 (53%)
- Biotechnology 17 (47%)
- Medical 12 (33%)
- Pharmaceutical 12 (33%)
- Medical Device 7 (19%)
Stage
- Seed 20 (56%)
- Venture - Series Unknown 7 (19%)
- Series A 4 (11%)
- Funding Round 2 (6%)
- Angel 1 (3%)
Country
- United Kingdom 29 (81%)
- Italy 1 (3%)
- Germany 1 (3%)
- Ireland 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
David Whitcombe
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
David Whitcombe
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
Gareth King
Life Science Partner
|
Life Science Partner | Total investments: 2 | Find email | |
Chris Spencer
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
Kevin D'Silva
Venture Partner - Medical Devices
|
Venture Partner - Medical Devices | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Infex Therapeutics acquire, develop and license drugs to treat pandemic infections. | $5.8M / Venture - Series Unknown / May 12, 2026 | ||
| ScubaTx device will commercialize Persufflation, a tried-and-true but underutilized method of organ preservation, by using industry-leading software design talents, deliver significant net savings to healthcare providers, enabling them to expand the supply of organs that can sustain life. | $1.9M / Seed / May 15, 2023 | ||
| Monument Therapeutics is a biotechnology company intended to develop drugs to treat serious diseases of the central nervous system. | $3.6M / Seed / Jul 01, 2021 | ||
| Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Ourco-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients. | $1M / Seed / Jun 30, 2021 | ||
| Flynotes is an innovative digital consent platform, improving patient safety across healthcare. | Seed / Nov 24, 2020 | ||
| Panthera Biopartners is an independent site management organization run by a world-class team of experts finds patients and runs clinical trials on behalf of CROs and pharma companies across multiple therapeutic areas. | Series A / Sep 23, 2020 | ||
| CroBio is a biotechnology company developing microbial soil amendments that help crops withstand drought and improve fertilizer efficiency. CroBio's developed microbes produce a cellulose biomaterial around plant roots, creating a sponge-like matrix that enhances water retention, nutrient uptake, and soil biodiversity. This technology enablesfarmers to reduce nutrient runoff and input costs while improving yields sustainably. With operations in the UK, USA, and Brazil, and partnerships with leading agribusinesses and research institutions, CroBio is scaling biological solutions to transform global agriculture. | $94K / Seed / Jul 15, 2020 | ||
| Pencil Biosciences aims to develop a novel, programmable genome-modulation tool that overcomes the challenges associated with the technologies currently available. | $673.7K / Seed / Dec 12, 2019 | ||
| Anti-Microbial Research Centre aims to accelerate the development of new antibiotics by providing development services to companies around the world in return for a commercial share from new products developed. | $3M / Angel / Mar 25, 2019 | ||
| Clin-e-cal is a digital health company, | Venture - Series Unknown / Oct 05, 2018 | ||
| See all 36 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does GM&C Life Sciences Fund invest in?
GM&C Life Sciences Fund invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Venture - Series Unknown stage. Most of the 36 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is GM&C Life Sciences Fund's check size?
GM&C Life Sciences Fund typically joins rounds of $94k–$1.9M at Seed, $1.9M–$4.2M at Series A and $4.3M–$5.8M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds GM&C Life Sciences Fund participates in.
How do I contact GM&C Life Sciences Fund?
Public channels for GM&C Life Sciences Fund include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at GM&C Life Sciences Fund?
The team at GM&C Life Sciences Fund includes David Whitcombe (Venture Partner), David Whitcombe (Venture Partner) and Gareth King (Life Science Partner), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
